Olr326 inhibitors represent a class of chemical compounds that specifically interact with the Olfactory receptor 326 (Olr326), a member of the G-protein coupled receptor (GPCR) superfamily. These inhibitors are designed to bind to the Olr326 receptor, modulating its activity by preventing the binding of its natural ligands or disrupting the conformational changes necessary for signal transduction. Olr326, like other olfactory receptors, is typically involved in the detection of volatile molecules, contributing to the sense of smell. The inhibitors of Olr326 are structurally diverse, often designed to exploit specific binding pockets or allosteric sites on the receptor. The design and synthesis of these inhibitors require a deep understanding of the receptor's structure, often utilizing techniques like molecular docking, X-ray crystallography, and nuclear magnetic resonance (NMR) spectroscopy to identify key interaction points and optimize binding affinity and selectivity.
The chemical nature of Olr326 inhibitors can vary widely, but they often contain functional groups that enable strong interactions with the receptor, such as hydrogen bonding, hydrophobic interactions, or π-π stacking with aromatic residues in the receptor's binding site. The study of Olr326 inhibitors also involves assessing their physicochemical properties, such as solubility, stability, and the ability to penetrate cellular membranes, which are crucial for ensuring that the inhibitors reach and effectively interact with the receptor in a cellular environment. Research in this area also focuses on the potential off-target effects, ensuring that the inhibitors are selective for Olr326 over other olfactory receptors or GPCRs. This specificity is essential for understanding the precise role of Olr326 in olfactory signaling pathways and its broader implications in sensory biology. The ongoing study of Olr326 inhibitors contributes to the broader understanding of GPCR function, receptor-ligand interactions, and the chemical principles that govern receptor modulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, altering downstream signaling that could affect Olr326 activity indirectly. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, potentially disrupting signaling pathways relevant to Olr326's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Targets mTOR, which could modify Olr326 activity by impacting cell growth and proliferation pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially affecting Olr326 by altering stress and inflammatory response pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor, could impact Olr326 activity by modulating the MAPK/ERK signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor, potentially affecting Olr326 by altering cell differentiation and proliferation signals. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Broad-spectrum tyrosine kinase inhibitor, could alter signaling pathways involving Olr326. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Cyclin-dependent kinase inhibitor, potentially impacting Olr326 activity related to cell cycle regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially affecting Olr326 activity by modulating apoptosis and cell survival pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor, could disrupt signaling pathways that influence Olr326 activity. | ||||||